INKT – mink therapeutics, inc. (US:NASDAQ)
Stock Stats
News
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress [Yahoo! Finance]
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target raised by analysts at HC Wainwright from $9.00 to $35.00. They now have a "buy" rating on the stock.
Form 10-K MiNK Therapeutics, Inc. For: Dec 31
Form 8-K MiNK Therapeutics, Inc. For: Mar 18
Form 4 MiNK Therapeutics, Inc. For: Mar 03 Filed by: WIINBERG ULF
Form 4 MiNK Therapeutics, Inc. For: Mar 03 Filed by: Behner Peter
Form 4 MiNK Therapeutics, Inc. For: Mar 03 Filed by: Kadlec Robert Peter
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.